Brief: Acer Announces Resubmission Of NDA For Acer-001 For Treatment Of UCDs
18/07/2022 14:14
July 18 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS ANNOUNCES RESUBMISSION OF NEW DRUG
APPLICATION
FOR ACER-001 FOR TREATMENT OF UCDS
* ACER THERAPEUTICS INC - BELIEVES RESUBMISSION ADDRESSES IN
FULL
ITEMS RAISED BY FDA IN COMPLETE RESPONSE LETTER (CRL)
* ACER THERAPEUTICS - NOTIFIED FDA IN RESUBMISSION THAT
THIRD-PARTY CONTRACT PACKAGING MANUFACTURER IS READY FOR
INSPECTION
Source text for Eikon: ID:nGNX8d2ClT
Further company coverage: ACER.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31